Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,508.26 +1,112.19 (+1.75%) CMC Crypto 200
1,334.09 +21.46 (+1.64%)
Novo Nordisk A/S (NONOF)
| Previous close | 122.81 |
| Open | 122.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 122.00 - 124.95 |
| 52-week range | 74.70 - 140.32 |
| Volume | |
| Avg. volume | 41,951 |
| Market cap | 548.992B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 46.23 |
| EPS (TTM) | 2.65 |
| Earnings date | N/A |
| Forward dividend & yield | 1.86 (1.51%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- Yahoo Finance Video
Weight loss drugs and the many use cases in medical treatments
Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases sprout up since these brand names' inceptions late last year. Yahoo Finance Health Reporter Anjalee Khemlani explains the new use cases being found for this class of drugs, including infertility treatments and even benefits for Alzheimer's patients. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.
ReutersIndia's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
ZacksEli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
